QQQ   294.11 (-0.17%)
AAPL   142.91 (-0.96%)
MSFT   246.85 (-0.39%)
META   148.69 (-0.19%)
GOOGL   98.08 (-0.77%)
AMZN   101.84 (-1.25%)
TSLA   171.63 (-0.92%)
NVDA   200.65 (+2.70%)
NIO   11.72 (-2.90%)
BABA   111.03 (+0.75%)
AMD   81.01 (+7.80%)
T   20.38 (+0.05%)
MU   61.58 (+2.12%)
F   13.65 (+1.04%)
CGC   2.98 (-1.65%)
GE   81.39 (+1.13%)
DIS   108.32 (-0.16%)
AMC   5.42 (+1.31%)
PFE   43.70 (-1.04%)
PYPL   80.77 (-0.88%)
NFLX   358.34 (+1.27%)
QQQ   294.11 (-0.17%)
AAPL   142.91 (-0.96%)
MSFT   246.85 (-0.39%)
META   148.69 (-0.19%)
GOOGL   98.08 (-0.77%)
AMZN   101.84 (-1.25%)
TSLA   171.63 (-0.92%)
NVDA   200.65 (+2.70%)
NIO   11.72 (-2.90%)
BABA   111.03 (+0.75%)
AMD   81.01 (+7.80%)
T   20.38 (+0.05%)
MU   61.58 (+2.12%)
F   13.65 (+1.04%)
CGC   2.98 (-1.65%)
GE   81.39 (+1.13%)
DIS   108.32 (-0.16%)
AMC   5.42 (+1.31%)
PFE   43.70 (-1.04%)
PYPL   80.77 (-0.88%)
NFLX   358.34 (+1.27%)
QQQ   294.11 (-0.17%)
AAPL   142.91 (-0.96%)
MSFT   246.85 (-0.39%)
META   148.69 (-0.19%)
GOOGL   98.08 (-0.77%)
AMZN   101.84 (-1.25%)
TSLA   171.63 (-0.92%)
NVDA   200.65 (+2.70%)
NIO   11.72 (-2.90%)
BABA   111.03 (+0.75%)
AMD   81.01 (+7.80%)
T   20.38 (+0.05%)
MU   61.58 (+2.12%)
F   13.65 (+1.04%)
CGC   2.98 (-1.65%)
GE   81.39 (+1.13%)
DIS   108.32 (-0.16%)
AMC   5.42 (+1.31%)
PFE   43.70 (-1.04%)
PYPL   80.77 (-0.88%)
NFLX   358.34 (+1.27%)
QQQ   294.11 (-0.17%)
AAPL   142.91 (-0.96%)
MSFT   246.85 (-0.39%)
META   148.69 (-0.19%)
GOOGL   98.08 (-0.77%)
AMZN   101.84 (-1.25%)
TSLA   171.63 (-0.92%)
NVDA   200.65 (+2.70%)
NIO   11.72 (-2.90%)
BABA   111.03 (+0.75%)
AMD   81.01 (+7.80%)
T   20.38 (+0.05%)
MU   61.58 (+2.12%)
F   13.65 (+1.04%)
CGC   2.98 (-1.65%)
GE   81.39 (+1.13%)
DIS   108.32 (-0.16%)
AMC   5.42 (+1.31%)
PFE   43.70 (-1.04%)
PYPL   80.77 (-0.88%)
NFLX   358.34 (+1.27%)
LON:HIK

Hikma Pharmaceuticals - HIK Share Forecast, Price & News

GBX 1,700
-8.50 (-0.50%)
(As of 02/1/2023 11:39 AM ET)
Add
Compare
Today's Range
1,686
▼
1,713.50
50-Day Range
1,481
▼
1,720.50
52-Week Range
1,174.50
▼
2,137
Volume
183,452 shs
Average Volume
440,044 shs
Market Capitalization
£3.74 billion
P/E Ratio
1,393.44
Dividend Yield
2.54%
Price Target
GBX 1,712.50

Hikma Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
2.8% Upside
GBX 1,754 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
-2.61
Upright™ Environmental Score
News Sentiment
0.25mentions of Hikma Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
£1.70 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.35 out of 5 stars

See Top Rated MarketRank™ Stocks Here

HIK stock logo

About Hikma Pharmaceuticals (LON:HIK) Stock

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Receive HIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

HIK Stock News Headlines

January 31, 2023 | americanbankingnews.com
Hikma Pharmaceuticals' (HIK) "Buy" Rating Reiterated at Citigroup
January 24, 2023 | marketwatch.com
Global Cancer Cachexia Therapeutics Market 2023 (New Exclusive Report) Size, Growth, Status, Latest Trend Insights to 2029
February 1, 2023 | PressReach (Ad)
Top Lithium Stock To Watch
Today's stock market news features a lithium stock with blue sky potential.
January 24, 2023 | marketwatch.com
Anaesthetic Medicines Market : Competitive Strategy Analysis and Forecast Values 2023-2028
January 23, 2023 | marketwatch.com
Global Generic Injectables Market Size Growth Rate Analysis 2023 by Production, Revenue, Price, Gross Margin, Countries and Forecast to 2027
January 20, 2023 | marketwatch.com
Total Intravenous Anesthesia (TIVA) Market 2023 : Future Trend, Business Strategies, Comprehensive Analysis and Forecast by 2028
January 19, 2023 | marketwatch.com
Antihypertensive Agents Market Size 2029 Size Estimation, New Investment Opportunities with Top Countries Data
January 18, 2023 | marketwatch.com
Cilostazol Market 2023 : Research Report Analysis Size Share Growth Research Report by Regional and Forecast to 2028
February 1, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
January 18, 2023 | marketwatch.com
Doxapram Hydrochloride Injection Market Size [2023-2029] | Industry Share, Growth Factor, Revenue And Trends Outlook Report
January 18, 2023 | marketwatch.com
Butorphanol Market : A Comprehensive Analysis of the Global Industry from 2023 to 2028, Including Size, Share, Growth, and Trends
January 17, 2023 | marketwatch.com
Generic Injectables Market Size: Overview, Share, Trends with Current Market Scenario, 2029
January 15, 2023 | marketwatch.com
Xerostomia (Dry Mouth Disease) Therapeutics Market 2023 : Research Report, Industry Growth, Competitors Analysis and Forecast 2028
January 14, 2023 | marketwatch.com
Cold Sore Treatment Market Trends, Business Overview, Industry Growth, and Forecast 2023 To 2028
January 12, 2023 | marketwatch.com
Famotidine Injection Market Size, Share, Growth, Revenue, Demand, Future Potential, and Forecast from 2023 to 2029
January 11, 2023 | marketwatch.com
Antihistamines Market Size 2023 : Segment Overview, Company Profiles, Regional Analysis and Forecast 2029
January 10, 2023 | marketwatch.com
Dexamethasone for COVID-19 Market 2023 by Industry Growth, Size, Trends, Share, Opportunities and Forecast To 2028
January 7, 2023 | marketwatch.com
Opioid Use Disorder Market Massive Growth Strikes Due To Technological Innovation During 2023-2028
January 5, 2023 | proactiveinvestors.com
Hikma Pharmaceuticals higher as Citi analysts revise target price
January 3, 2023 | msn.com
Hikma, Celltrion Healthcare sign licensing agreement for Vegzelma
January 3, 2023 | markets.businessinsider.com
FTSE 100 Rallies Led By Energy Stocks
January 3, 2023 | marketwatch.com
Hikma Pharmaceuticals Launches Xyrem Generic in the U.S.
January 3, 2023 | proactiveinvestors.com
Hikma Pharmaceuticals launches generic version of narcolepsy treatment Xyrem in US
December 21, 2022 | finance.yahoo.com
Hikma Pharmaceuticals PLC (LON:HIK) is largely controlled by institutional shareholders who own 50% of the company
December 19, 2022 | msn.com
Drug shortage ‘isn’t like what we had with baby formula’
December 19, 2022 | msn.com
Gottlieb: Drug shortage ‘isn’t like what we had with baby formula’
December 14, 2022 | marketwatch.com
Hikma Pharmaceuticals falls Wednesday, underperforms market
See More Headlines
Receive HIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

HIK Company Calendar

Today
2/01/2023
Next Earnings (Estimated)
2/23/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:HIK
CUSIP
N/A
CIK
N/A
Web
www.hikma.com
Phone
+44-20-73992760
Fax
N/A
Employees
8,700
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
GBX 1,754
High Stock Price Forecast
GBX 2,300
Low Stock Price Forecast
GBX 1,350
Forecasted Upside/Downside
+0.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
1,393.44
Forward P/E Ratio
1,036.99
P/E Growth
4.82
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
70.79
Current Ratio
2.12
Quick Ratio
1.27

Sales & Book Value

Annual Sales
£2.55 billion
Price / Sales
1.47
Cash Flow
GBX 203.86 per share
Price / Cash Flow
8.34
Book Value
GBX 988.60 per share
Price / Book
1.72

Miscellaneous

Outstanding Shares
220,230,000
Free Float
N/A
Market Cap
£3.74 billion
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Engineer Said Samih Taleb Darwazah (Age 65)
    Exec. Chairman & CEO
    Comp: $2.71M
  • Mr. Mazen Samih Taleb Darwazah (Age 64)
    Exec. Vice Chairman & Pres of MENA
    Comp: $2.11M
  • Mr. Khalid Waleed Hosny Al Nabilsi (Age 50)
    Chief Financial Officer
  • Mr. Hussein Arkhagha
    Company Sec. & Chief Counsel
  • Mr. Bassam Wael Rushdi Kanaan CFA (Age 57)
    CPA, Exec. VP of Corp. Devel. and M&A
  • Ms. Susan Ringdal
    Exec. VP of Strategic Planning & Global Affairs
  • Ms. Majda Labadi
    Exec. VP of Organisational Devel.
  • Mr. Riad Mishlawi
    Pres of Injectables
  • Mr. Brian Hoffmann
    Pres of Generics
  • Mr. Samuel Park
    Global Head of Intellectual Property (IP) & Gen. Counsel for US

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions













HIK Stock - Frequently Asked Questions

Should I buy or sell Hikma Pharmaceuticals stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" HIK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HIK, but not buy additional shares or sell existing shares.
View HIK analyst ratings or view top-rated stocks.

What is Hikma Pharmaceuticals' stock price forecast for 2023?

5 brokers have issued 1 year price objectives for Hikma Pharmaceuticals' stock. Their HIK share price forecasts range from GBX 1,350 to GBX 2,300. On average, they expect the company's share price to reach GBX 1,754 in the next year. This suggests a possible upside of 2.8% from the stock's current price.
View analysts price targets for HIK or view top-rated stocks among Wall Street analysts.

How have HIK shares performed in 2023?

Hikma Pharmaceuticals' stock was trading at GBX 1,552 at the beginning of the year. Since then, HIK shares have increased by 10.0% and is now trading at GBX 1,707.
View the best growth stocks for 2023 here.

When is Hikma Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our HIK earnings forecast.

How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?

Hikma Pharmaceuticals announced a dividend on Thursday, August 4th. Investors of record on Thursday, August 18th will be given a dividend of GBX 0.19 per share on Monday, September 19th. This represents a yield of 0.89%. The ex-dividend date is Thursday, August 18th. The official announcement can be viewed at this link.
Read our dividend analysis for HIK.

Is Hikma Pharmaceuticals a good dividend stock?

Hikma Pharmaceuticals (LON:HIK) pays an annual dividend of GBX 0.52 per share and currently has a dividend yield of 2.54%. The dividend payout ratio is 42.65%. This payout ratio is at a healthy, sustainable level, below 75%.
Read our dividend analysis for HIK.

What other stocks do shareholders of Hikma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hikma Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Gran Tierra Energy (GTE), Och-Ziff Capital Management Group (OZM) and Belden (BDC).

What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HIK."

How do I buy shares of Hikma Pharmaceuticals?

Shares of HIK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Hikma Pharmaceuticals' stock price today?

One share of HIK stock can currently be purchased for approximately GBX 1,707.

How much money does Hikma Pharmaceuticals make?

Hikma Pharmaceuticals (LON:HIK) has a market capitalization of £3.76 billion and generates £2.55 billion in revenue each year.

How many employees does Hikma Pharmaceuticals have?

The company employs 8,700 workers across the globe.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The official website for the company is www.hikma.com. The company can be reached via phone at +44-20-73992760.

This page (LON:HIK) was last updated on 2/1/2023 by MarketBeat.com Staff